Abuse of Prescription Drugs in the Context of Novel Psychoactive Substances (NPS): A Systematic Review
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Recently, a range of prescription and over-the-counter drugs have been reportedly used as Novel Psychoactive Substances (NPS), due to their potential for abuse resulting from their high dosage/idiosyncratic methods of self-administration. This paper provides a systematic review of the topic, focusing on a range of medications which have emerged as being used recreationally, either on their own or in combination with NPS. Among gabapentinoids, pregabalin may present with higher addictive liability levels than gabapentin, with pregabalin being mostly identified in the context of opioid, polydrug intake. For antidepressants, their dopaminergic, stimulant-like, bupropion activities may explain their recreational value and diversion from the therapeutic intended use. In some vulnerable clients, a high dosage of venlafaxine (‘baby ecstasy’) is ingested for recreational purposes, whilst the occurrence of a clinically-relevant withdrawal syndrome may be a significant issue for all venlafaxine-treated patients. Considering second generation antipsychotics, olanzapine appears to be ingested at very large dosages as an ‘ideal trip terminator’, whilst the immediate-release quetiapine formulation may possess proper abuse liability levels. Within the image- and performance- enhancing drugs (IPEDs) group, the beta-2 agonist clenbuterol (‘size zero pill’) is reported to be self-administered for aggressive slimming purposes. Finally, high/very high dosage ingestion of the antidiarrhoeal loperamide has shown recent increasing levels of popularity due to its central recreational, anti-withdrawal, opiatergic effects. The emerging abuse of prescription drugs within the context of a rapidly modifying drug scenario represents a challenge for psychiatry, public health and drug-control policies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Di Chiara, G., & Imperato, A. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.14.5274 · Cited by 4,733
Trends in Prescription Drug Use Among Adults in the United States From 1999-2012
Kantor, E. D., Rehm, C. D., Haas, J. S., Chan, A. T., & Giovannucci, E. L. (2015) · JAMA · doi:10.1001/jama.2015.13766 · Cited by 1,219
Carvalho, A. F., Sharma, M. S., Brunoni, A. R., Vieta, E., & Fava, G. A. (2016) · Psychotherapy and Psychosomatics · doi:10.1159/000447034 · Cited by 650
Stahl, S. M., Pradko, J., Haight, B. R., Modell, J. G., Rockett, C. B., & Learned-Coughlin, S. (2004) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.v06n0403 · Cited by 495 · cited 1×
“Bupropion pharmacology relies on its action both as a selective inhibitor of catecholamines (noradrenaline and DA) reuptake [35,36], and as a non-competitive antagonist of nicotinic acetylcholine receptors, hence being prescribed as well as an aid in smoking cessation [36].”
BackgroundAtypical antipsychotics: new directions and new challenges in the treatment of schizophrenia
Kapur, S., & Remington, G. (2001) · Annual Review of Medicine · doi:10.1146/annurev.med.52.1.503 · Cited by 324
Novel psychoactive substances of interest for psychiatry
Schifano, F., Orsolini, L., Duccio Papanti, G., & Corkery, J. M. (2015) · World Psychiatry · doi:10.1002/wps.20174 · Cited by 321
Self-citationEvidence of the dual mechanisms of action of venlafaxine
Harvey, A. T., Rudolph, R. L., & Preskorn, S. H. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.5.503 · Cited by 302 · cited 1×
“Venlafaxine’s main active metabolite, desvenlafaxine, is highly inhibitive of NE transporter activities, further increasing the rate of DA turnover in the prefrontal cortex [49].”
BackgroundChiappini, S., & Schifano, F. (2016) · CNS Drugs · doi:10.1007/s40263-016-0359-y · Cited by 189 · cited 9×
“According to the Proportional Reporting Ratio (PRR) computation, abuse/dependence issues were more frequently reported for pregabalin compared with gabapentin, hence confirming its higher addictive liability levels [7,22].”
BackgroundInfluentialSelf-citationTauscher, J., Hussain, T., Agid, O., Verhoeff, N. P. L. G., Wilson, A. A., Houle, S., Remington, G., Zipursky, R. B., & Kapur, S. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.9.1620 · Cited by 159
KUROKI, T., NAGAO, N., & NAKAHARA, T. (2008) · Progress in brain research · doi:10.1016/s0079-6123(08)00910-2 · Cited by 146
Research works printed but not linked: 134
- Zawilska, 2015, Next generation of novel psychoactive substances on the horizon—A complex problem to face, Drug Alcohol Depend., 157, 1, 10.1016/j.drugalcdep.2015.09.030 · DOI · Paper page
- Hearne, 2017, New psychoactive substances (NPS) on crypto market fora: An exploratory study of characteristics of forum activity between NPS buyers and vendors, Int. J. Drug Policy, 40, 102, 10.1016/j.drugpo.2016.11.007 · DOI
- Soussan, 2018, The diverse reasons for using Novel Psychoactive Substances—A qualitative study of the users’ own perspectives, Int. J. Drug Policy, 52, 71, 10.1016/j.drugpo.2017.11.003 · DOI
- Chiappini, 2018, Is there a potential of misuse for quetiapine? Literature review and analysis of the European Medicines Agency/EMA Adverse Drug Reactions’ database, J. Clin. Psychopharmacol., 38, 72, 10.1097/JCP.0000000000000814 · DOI · Paper page
- Milano, G., Chiappini, S., Mattioli, F., Martelli, A., and Schifano, F. (2018). β-2 agonists as misusing Drugs? Assessment of both Clenbuterol- and Salbutamol-related European Medicines Agency (EMA) Pharmacovigilance Database Reports. Basic Clin. Pharmacol. Toxicol., 2. · DOI
- Lasoff, 2017, Loperamide Trends in Abuse and Misuse Over 13 Years: 2002–2015, Pharmacotherapy, 37, 249, 10.1002/phar.1885 · DOI
- Schifano, 2014, Misuse and Abuse of Pregabalin and Gabapentin: Cause for Concern?, CNS Drugs, 28, 491, 10.1007/s40263-014-0164-4 · DOI · Paper page
- Evoy, 2017, Abuse and Misuse of Pregabalin and Gabapentin, Drugs, 77, 403, 10.1007/s40265-017-0700-x · DOI · Paper page
- Schjerning, 2016, Abuse Potential of Pregabalin: A Systematic Review, CNS Drugs, 30, 9, 10.1007/s40263-015-0303-6 · DOI · Paper page
- Schjerning, 2016, Use of Pregabalin—A Nationwide Pharmacoepidemiological Drug Utilization Study with Focus on Abuse Potential, Pharmacopsychiatry, 49, 155, 10.1055/s-0042-101868 · DOI
- Bonnet, 2017, How addictive are gabapentin and pregabalin? A systematic review, Eur. Neuropsychopharmacol., 27, 1185, 10.1016/j.euroneuro.2017.08.430 · DOI · Paper page
- Daly, C., Griffin, E., Ashcroft, D.M., Webb, R.T., Perry, I.J., and Arensman, E. (2017). Intentional Drug Overdose Involving Pregabalin and Gabapentin: Findings from the National Self-Harm Registry Ireland, 2007–2015. Clin. Drug Investig., 20. · DOI
- Reeves, 2014, Potentiation of the effect of buprenorphine/naloxone with gabapentin or quetiapine, Am. J. Psychiatry, 171, 691, 10.1176/appi.ajp.2014.13111526 · DOI · Paper page
- (2018, April 21). Greater use of gabapentinoids in intentional drug overdose. Available online: https://doi.org/10.1007/s40278-018-40617-3. · doi:10.1007/s40278-018-40617-3
- Anderson, 2017, Using Social Listening Data to Monitor Misuse and Nonmedical Use of Bupropion: A Content Analysis, JMIR Public Health Surveill., 3, e6, 10.2196/publichealth.6174 · DOI
- Evans, 2014, Abuse and misuse of antidepressants, Subst. Abuse Rehabil., 5, 107
- Welsh, 2002, Seizure-induced by insufflation of bupropion, N. Engl. J. Med., 347, 951, 10.1056/NEJM200209193471222 · DOI
- Reeves, 2013, Additional evidence of the abuse potential of bupropion, J. Clin. Psychopharmacol., 33, 584, 10.1097/JCP.0b013e318295fe2f · DOI
- Baribeau, 2013, Intravenous bupropion: A previously undocumented method of abuse of a commonly prescribed antidepressant agent, J. Addict. Med., 7, 216, 10.1097/ADM.0b013e3182824863 · DOI
- Prosser, 2012, The toxicology of bath salts: A review of synthetic cathinones, J. Med. Toxicol., 8, 33, 10.1007/s13181-011-0193-z · DOI · Paper page
- Stall, 2014, Bupropion abuse and overdose, CMAJ, 186, 1015, 10.1503/cmaj.131534 · DOI
- Stassinos, 2016, Bupropion “Abuse” Reported to US Poison Centers, J. Addict. Med., 10, 357, 10.1097/ADM.0000000000000249 · DOI
- Hill, 2007, Letter to the editor. A case report of seizure induced by bupropion nasal insufflation, J. Clin. Psychiatry, 9, 67
- Yoon, 2013, Intranasal bupropion abuse case report, Am. J. Addict., 22, 180, 10.1111/j.1521-0391.2013.00329.x · DOI
- Hilliard, 2013, Bupropion diversion and misuse in the correctional facility, J. Correct. Health Care, 19, 211, 10.1177/1078345813486448 · DOI
- Phillips, 2012, Wellbutrin: Misuse and abuse by incarcerated individuals, J. Addict. Nurs., 23, 65, 10.3109/10884602.2011.647838 · DOI
- Maj, 1999, Pharmacological effects of venlafaxine, a new antidepressant, given repeatedly, on the alpha 1-adrenergic, DA and serotonin systems, J. Neural Transm., 106, 197, 10.1007/s007020050151 · DOI
- Rakun, 2011, Venlafaxine withdrawal syndrome, Psychiatr. Danub., 23, 117
- Fava, 1997, Emergence of adverse events following discontinuation of treatment with extended-release venlafaxine, Am. J. Psychiatry, 12, 1760, 10.1176/ajp.154.12.1760 · DOI · Paper page
- Stahl, 2005, SNRIs: Their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants, CNS Spectr., 10, 732, 10.1017/S1092852900019726 · DOI · Paper page
- Llorca, 2007, Escitalopram in the treatment of major depressive disorder: Clinical efficacy, tolerability and cost-effectiveness vs. venlafaxine extended-release formulation, Int. J. Clin. Pract., 61, 702, 10.1111/j.1742-1241.2007.01335.x · DOI · Paper page
- Kotzalidis, 2008, Similar discontinuation symptoms for withdrawal from medium-dose paroxetine and venlafaxine, J. Psychopharmacol., 22, 581, 10.1177/0269881107081562 · DOI · Paper page
- Holland, 2017, Neonatal venlafaxine discontinuation syndrome: A mini-review, Eur. J. Paediatr. Neurol., 21, 264, 10.1016/j.ejpn.2016.11.003 · DOI
- Cutler, N. (2017). Severe Venlafaxine Withdrawal Successfully Treated With a Short Course of Duloxetine. Prim. Care Companion CNS Disord., 19. · DOI
- Groot, 2013, Consensus group Tapering. [Tapering strips for paroxetine and venlafaxine], Tijdschr. Psychiatr., 55, 789
- Francesconi, 2015, Venlafaxine as the ‘baby ecstasy’? Literature overview and analysis of web-based misusers’ experiences, Hum. Psychopharmacol., 30, 255, 10.1002/hup.2476 · DOI · Paper page
- Sattar, 2003, A case of venlafaxine abuse, N. Engl. J. Med., 348, 764, 10.1056/NEJM200302203480822 · DOI
- (2018, April 21). Venlafaxine overdose. Available online: https://doi.org/10.1007/s40278-018-40604-4. · doi:10.1007/s40278-018-40604-4
- Baker, 2014, Illicit and pharmaceutical drug consumption estimated via wastewater analysis. Part A: Chemical analysis and drug use estimates, Sci. Total Environ., 487, 629, 10.1016/j.scitotenv.2013.11.107 · DOI · Paper page
- Fountain, 2016, TOXINZ, the New Zealand Internet poisons information database: The first decade, Emerg. Med. Australas., 28, 335, 10.1111/1742-6723.12594 · DOI
- Bogart, 2011, Abuse of second-generation antipsychotics: What prescribers need to know, Curr. Psychiatry, 10, 77
- Sarker, 2016, Social Media Mining for Toxicovigilance: Automatic Monitoring of Prescription Medication Abuse from Twitter, Drug Saf., 39, 231, 10.1007/s40264-015-0379-4 · DOI · Paper page
- Majadas, 2008, Quetiapine in the treatment of sleep disturbances associated with addictive conditions: A retrospective study, Subst. Use Misuse, 43, 2169, 10.1080/10826080802290240 · DOI
- Srivastava, 2013, A Case Series of Quetiapine Addiction/Dependence, Ger. J. Psychiatr., 16, 152
- Kim, 2017, Quetiapine Misuse and Abuse: Is it an Atypical Paradigm of Drug-Seeking Behavior?, J. Res. Pharm. Pract., 6, 12, 10.4103/2279-042X.200987 · DOI · Paper page
- Waters, 2007, Intravenous Quetiapine-Cocaine Use (“Q-Ball”), Am. J. Psychiatry, 164, 173, 10.1176/ajp.2007.164.1.173a · DOI
- Pierre, 2004, Intranasal quetiapine abuse, Am. J. Psychiatry, 61, 1718, 10.1176/appi.ajp.161.9.1718 · DOI
- George, M., Haasz, M., Coronado, A., Salhanick, S., Korbel, L., and Kitzmiller, J.P. (2013). Acute dyskinesia, myoclonus, and akathisia in an adolescent male abusing quetiapine via nasal insufflation: A case study. BMC Pediatr., 13. · DOI
- Morin, 2007, Possible intranasal quetiapine misuse, Am. J. Health Syst. Pharm., 64, 723, 10.2146/ajhp060226 · DOI · Paper page
- Reeves, 2007, Additional evidence of the abuse potential of quetiapine, South. Med. J., 100, 834, 10.1097/SMJ.0b013e3180f62d53 · DOI · Paper page
- Paparrigopoulos, 2008, Quetiapine: Another drug with potential for misuse? A case report, J. Clin. Psychiatry, 69, 162, 10.4088/JCP.v69n0122a · DOI · Paper page
- Chen, 2009, Dependence on quetiapine in combination with zolpidem and clonazepam in bipolar depression, Psychiatry Clin. Neurosci., 63, 427, 10.1111/j.1440-1819.2009.01953.x · DOI · Paper page
- Sansone, 2010, Is Seroquel developing an illicit reputation for misuse/abuse?, Psychiatry, 7, 13
- Diot, 2015, Réseau de centres de d’Addictovigilance. Abuse Liability of Quetiapine (Xeroquel®): Analysis of the literature, Fundam. Clin. Pharmacol., 29, 27
- Haller, E., Bogunovic, O., and Miller, M. (2013, January 7). Atypical antipsychotics new drugs of abuse. Proceedings of the American Academy of Addiction Psychiatry (AAAP) 24th Annual Meeting & Symposium, Scottsdale, AZ, USA. Abstract 16.
- Mattson, 2015, Emergency Department Visits Involving Misuse and Abuse of the Antipsychotic Quetiapine: Results from the Drug Abuse Warning Network (DAWN), Subst. Abuse, 9, 39
- Klein, 2017, Intentional Recreational Abuse of Quetiapine Compared to Other Second-generation Antipsychotics, West. J. Emerg. Med., 18, 243, 10.5811/westjem.2016.10.32322 · DOI · Paper page
- Pinta, 2007, Letter to the editor. Quetiapine Addiction?, Am. J. Psychiatry, 164, 1, 10.1176/ajp.2007.164.1.174 · DOI
- Cha, 2013, Dependence potential of quetiapine: Behavioral pharmacology in rodents, Biomol. Ther., 21, 307, 10.4062/biomolther.2013.035 · DOI
- Kapur, 2000, Antipsychotic agents differ in how fast they come off the DA D2 receptors. Implications for atypical antipsychotic action, J. Psychiatry Neurosci., 25, 161
- Montebello, 2017, Misuse and Associated Harms of Quetiapine and Other Atypical Antipsychotics, Curr. Top. Behav. Neurosci., 34, 125, 10.1007/7854_2015_424 · DOI
- Navailles, 2011, Presynaptic control of serotonin on striatal DA function, Psychopharmacology, 213, 213, 10.1007/s00213-010-2029-y · DOI
- Kotagale, 2013, Evidences for the involvement of sigma receptors in antidepressant-like effect of quetiapine in mice, Eur. J. Pharmacol., 702, 180, 10.1016/j.ejphar.2013.01.045 · DOI
- Yasui, Y., and Su, T.P. (2016). Potential Molecular Mechanisms on the Role of the Sigma-1 Receptor in the Action of Cocaine and Methamphetamine. J. Drug Alcohol Res., 5. · DOI
- Grabowski, 2017, Quetiapine abuse and dependence: Is pharmacokinetics important?, Acta Clin. Belg., 13, 1
- Dahr, 2010, Olanzapine Dependence, Ger. J. Psychiatry, 13, 51
- James, 2016, Non-medical use of olanzapine by people on methadone treatment, BJPsych Bull., 40, 314, 10.1192/pb.bp.115.052886 · DOI · Paper page
- Skilbeck, 2007, The effects of antipsychotic drugs on GABAA receptor binding depend on period of drug treatment and binding site examined, Schizophr. Res., 90, 76, 10.1016/j.schres.2006.11.009 · DOI
- Egerton, 2008, Modulation of striatal DA release by 5-HT2A and 5-HT2C receptor antagonists: [11C]raclopride PET studies in the rat, Psychopharmacology, 200, 487, 10.1007/s00213-008-1226-4 · DOI
- Skov, 2015, Postmortem Quetiapine Reference Concentrations in Brain and Blood, J. Anal. Toxicol., 39, 557, 10.1093/jat/bkv072 · DOI
- Vance, 2009, Postmortem Tissue Concentrations of Olanzapine, J. Anal. Toxicol., 33, 15, 10.1093/jat/33.1.15 · DOI
- (2018, April 21). Aspirin/paracetamol/quetiapine overdose. Available online: https://doi.org/10.1007/s40278-018-40658-z. · doi:10.1007/s40278-018-40658-z
- (2018, April 21). Quetiapine/trazodone overdose. Available online: https://doi.org/10.1007/s40278-018-40528-4. · doi:10.1007/s40278-018-40528-4
- McVeigh, 2012, Human enhancement drugs and the pursuit of perfection, Adicciones, 24, 185, 10.20882/adicciones.88 · DOI
- Corazza, 2014, The diffusion of Performance and Image-Enhancing Drugs (IPEDs) on the Internet: The Abuse of the Cognitive Enhancer Piracetam, Subst. Use Misuse, 49, 1849, 10.3109/10826084.2014.912232 · DOI · Paper page
- Sagoe, 2015, Polypharmacy among anabolic-androgenic steroid users: A descriptive metasynthesis, Subst. Abuse Treat. Prev. Policy, 10, 12, 10.1186/s13011-015-0006-5 · DOI · Paper page
- Brennan, 2017, The injecting use of image and performance-enhancing drugs (IPED) in the general population: A systematic review, Health Soc. Care Community, 25, 1459, 10.1111/hsc.12326 · DOI
- Kean, 2015, An exploratory study of image and performance enhancement drug use in a male British South Asian community, Int. J. Drug Policy, 26, 860, 10.1016/j.drugpo.2015.03.002 · DOI
- Rowe, 2017, Risk and blood-borne virus testing among men who inject image and performance enhancing drugs, Sydney, Australia, Drug Alcohol Rev., 36, 658, 10.1111/dar.12467 · DOI
- Koenraadt, 2017, Exploring the relationship between online buyers and sellers of image and performance enhancing drugs (IPEDs): Quality issues, trust and self-regulation, Int. J. Drug Policy, 50, 48, 10.1016/j.drugpo.2017.09.004 · DOI
- Albertson, 2016, The Changing Drug Culture: Use and Misuse of Appearance- and Performance-Enhancing Drugs, FP Essent., 441, 30
- Cassidy, 1999, Insulin as a substance of misuse in a patient with insulin dependent diabetes mellitus, BMJ, 319, 1417, 10.1136/bmj.319.7222.1417 · DOI
- Grimmer, 2016, Rhabdomyolysis Secondary to Clenbuterol Use and Exercise, J. Emerg. Med., 50, e71, 10.1016/j.jemermed.2015.09.006 · DOI
- Mottram, D.R., and Chester, N. (2014). Drugs in Sports, Routledge. [6th ed.]. · doi:10.4324/9781315881935
- Quinley, 2016, Clenbuterol causing non-ST-segment elevation myocardial infarction in a teenage female desiring to lose weight: Case and brief literature review, Am. J. Emerg. Med., 34, 1739, 10.1016/j.ajem.2015.12.086 · doi:10.1016/j.ajem.2015.12.086
- Khalil, 2017, Clenbuterol Hydrochloride, Profiles Drug Subst. Excip. Relat. Methodol., 42, 91, 10.1016/bs.podrm.2017.02.002 · doi:10.1016/bs.podrm.2017.02.002
- Spiller, 2013, A descriptive study of adverse events from clenbuterol misuse and abuse for weight loss and bodybuilding, Subst. Abuse, 34, 306, 10.1080/08897077.2013.772083 · DOI
- Brett, 2014, Clenbuterol toxicity: A NSW poisons information centre experience, Med. J. Aust., 200, 219, 10.5694/mja13.10982 · DOI
- Tutelyan, 2013, Dietary supplements containing prohibited substances, Vopr. Pitan, 82, 6
- Solimini, 2017, Adulteration Practices of Psychoactive Illicit Drugs: An Updated Review, Curr. Pharm. Biotechnol., 18, 524, 10.2174/1389201018666170710184531 · doi:10.2174/1389201018666170710184531
- Barry, 2013, Case report and review of clenbuterol cardiac toxicity, J. Cardiol. Cases, 8, 131, 10.1016/j.jccase.2013.07.004 · doi:10.1016/j.jccase.2013.07.004
- Huckins, 2013, Myocardial ischemia associated with clenbuterol abuse: Report of two cases, J. Emerg. Med., 44, 444, 10.1016/j.jemermed.2012.02.057 · doi:10.1016/j.jemermed.2012.02.057
- Daubert, 2007, Acute clenbuterol overdose resulting in supraventricular tachycardia and atrial fibrillation, J. Med. Toxicol., 3, 56, 10.1007/BF03160909 · doi:10.1007/bf03160909
- Ferrua, 2009, Acute myocardial infarction due to coronary vasospasm and salbutamol abuse, Heart, 95, 673, 10.1136/hrt.2008.161638 · DOI
- Marte, 2010, Atrial fibrillation associated with chocolate intake abuse and chronic salbutamol inhalation abuse, Int. J. Cardiol., 145, e74, 10.1016/j.ijcard.2008.12.159 · DOI
- Boucher, 2011, Salbutamol misuse or abuse with fatal outcome: A case report, Hum. Exp. Toxicol., 30, 1869, 10.1177/0960327110388957 · DOI
- 1987, Effects of clenbuterol and prenalterol on performance during differential reinforcement of low response rate in the rat, J. Pharmacol. Exp. Ther., 241, 68, 10.1016/S0022-5347(25)00358-1 · DOI
- Edwards, 1979, Dependency upon salbutamol inhalers, Br. J. Psychiatry, 134, 624, 10.1192/bjp.134.6.624 · doi:10.1192/bjp.134.6.624
- Morgan, 1986, Pharmacokinetics of intravenous and oral salbutamol and its sulphate conjugate, Br. J. Clin. Pharmacol., 22, 587, 10.1111/j.1365-2125.1986.tb02939.x · DOI · Paper page
- Pope, 2013, Adverse health consequences of performance-enhancing drugs: An Endocrine Society scientific statement, Endocr. Rev., 35, 341, 10.1210/er.2013-1058 · DOI · Paper page
- Lewis, 1993, A study of self- poisoning with oral salbutamol-laboratory and clinical features, Hum. Exp. Toxicol., 12, 397, 10.1177/096032719301200509 · doi:10.1177/096032719301200509
- Nicoli, 2013, Quantification of clenbuterol at trace level in human urine by ultra-high pressure liquid chromatography-tandem mass spectrometry, J. Chromatogr. A, 1292, 142, 10.1016/j.chroma.2012.12.008 · DOI
- Vaso, 2015, Use and abuse of medication during 2014 FIFA World Cup Brazil: A retrospective survey, BMJ Open, 5, E007608, 10.1136/bmjopen-2015-007608 · DOI
- Miller, 2017, Loperamide misuse and abuse, J. Am. Pharm. Assoc., 57, S45, 10.1016/j.japh.2016.12.079 · DOI
- Daniulaityte, 2013, “I just wanted to tell you that loperamide WILL WORK”: A web-based study of the extra-medical use of loperamide, Drug Alcohol Depend., 130, 241, 10.1016/j.drugalcdep.2012.11.003 · DOI
- Levine, 2007, “Pharming”: The abuse of prescription and over-the-counter drugs in teens, Curr. Opin. Pediatr., 19, 270, 10.1097/MOP.0b013e32814b09cf · DOI · Paper page
- Cooper, 2013, Over the counter medicine abuse—A review of the literature, J. Subst. Use, 18, 82, 10.3109/14659891.2011.615002 · DOI · Paper page
- Fox, 2005, The birth of the e-clinic. Continuity or transformation in the UK governance of pharmaceutical consumption?, Soc. Sci. Med., 61, 1474, 10.1016/j.socscimed.2005.03.011 · DOI
- Manchikanti, 2006, Prescription drug abuse: What is being done to address this new drug epidemic? Testimony before the Subcommittee on Criminal Justice, Drug Policy and Human Resources, Pain Physician, 9, 287
- Baker, 2007, Loperamide: A pharmacological review, Rev. Gastroenterol. Disord., 7, S11-8
- Jaffe, 1980, Abuse potential of loperamide, Clin. Pharmacol. Ther., 28, 812, 10.1038/clpt.1980.239 · DOI
- Wightman, 2016, Not your regular high: Cardiac dysrhythmias caused by loperamide, Clin. Toxicol., 54, 454, 10.3109/15563650.2016.1159310 · DOI
- Borron, 2017, Misuse and Abuse of Loperamide: A New Look at a Drug with “Low Abuse Potential”, J. Emerg. Med., 53, 73, 10.1016/j.jemermed.2017.03.018 · DOI
- Marraffa, 2014, Cardiac conduction disturbance after loperamide abuse, Clin. Toxicol., 52, 952, 10.3109/15563650.2014.969371 · DOI
- Stanciu, 2017, Loperamide, the “Poor Man’s Methadone”: Brief Review, J. Psychoact. Drugs, 49, 18, 10.1080/02791072.2016.1260188 · DOI
- Eggleston, 2016, Notes from the Field: Cardiac Dysrhythmias after Loperamide Abuse—New York, 2008–2016, MMWR Morb. Mortal Wkly. Rep., 65, 1276, 10.15585/mmwr.mm6545a7 · DOI
- Eggleston, 2017, Loperamide Abuse Associated With Cardiac Dysrhythmia and Death, Ann. Emerg. Med., 69, 83, 10.1016/j.annemergmed.2016.03.047 · DOI
- Bhatti, 2017, Loperamide metabolite-induced cardiomyopathy and QTc prolongation, Clin. Toxicol., 55, 659, 10.1080/15563650.2017.1304555 · DOI
- Kozak, 2017, Torsades de pointes with high-dose loperamide, J. Electrocardiol., 50, 355, 10.1016/j.jelectrocard.2017.01.011 · DOI
- Wu, 2017, Clinical Review: Loperamide Toxicity, Ann. Emerg. Med., 70, 245, 10.1016/j.annemergmed.2017.04.008 · DOI
- Feaster, 2016, Loperamide-Related Deaths in North Carolina, J. Anal. Toxicol., 40, 677, 10.1093/jat/bkw069 · DOI
- Swank, 2017, Adverse event detection using the FDA post-marketing drug safety surveillance system: Cardiotoxicity associated with loperamide abuse and misuse, J. Am. Pharm. Assoc., 57, S63, 10.1016/j.japh.2016.11.011 · DOI
- Church, 1994, Loperamide blocks high-voltage-activated calcium channels and N-methyl-D-aspartate-evoked responses in rat and mouse cultured hippocampal pyramidal neurons, Mol. Pharmacol., 45, 747, 10.1016/S0026-895X(25)10162-4 · DOI
- Yaksh, 1999, Characterization of the antihyperalgesic action of a novel peripheral mu-opioid receptor agonist- loperamide, Anesthesiology, 90, 225, 10.1097/00000542-199901000-00029 · DOI
- Kang, 2016, Proarrhythmic mechanisms of the common anti-diarrheal medication loperamide: Revelations from the opioid abuse epidemic, Naunyn Schmiedebergs Arch. Pharmacol., 389, 1133, 10.1007/s00210-016-1286-7 · DOI
- Zhou, 2004, Herbal modulation of P-glycoprotein, Drug Metab. Rev., 36, 57, 10.1081/DMR-120028427 · DOI · Paper page
- Corazza, 2013, Promoting innovation and excellence to face the rapid diffusion of novel psychoactive substances in the EU: The outcomes of the ReDNet project, Hum. Psychopharmacol., 28, 317, 10.1002/hup.2299 · DOI · Paper page
- Larsen, 2018, Ventricular Tachycardia Triggered by Loperamide and Famotidine Abuse, Drug Saf. Case Rep., 5, 11, 10.1007/s40800-018-0077-0 · doi:10.1007/s40800-018-0077-0
- Sehring, 2017, Letter to the editor. Loperamide abuse and cardiotoxicity, J. Community Hosp. Intern. Med. Perspect., 7, 275, 10.1080/20009666.2017.1361294 · doi:10.1080/20009666.2017.1361294
- Orsolini, 2015, Mind navigators of chemicals’ experimenters? A web-based description of e-psychonauts, Cyberpsychol. Behav. Soc. Netw., 18, 296, 10.1089/cyber.2014.0486 · DOI · Paper page
- Johanson, 2009, Risk management post-marketing surveillance for the abuse of medications acting on the central nervous system: Expert panel report, Drug Alcohol Depend., 105, S65, 10.1016/j.drugalcdep.2009.08.006 · DOI
- Mackey, 2016, Digital danger: A review of the global public health, patient safety and cybersecurity threats posed by illicit online pharmacies, Br. Med. Bull., 118, 110, 10.1093/bmb/ldw016 · doi:10.1093/bmb/ldw016
- McColl, 2006, Research design strategies to evaluate the impact of formulations on abuse liability, Drug Alcohol Depend., 83, S52, 10.1016/j.drugalcdep.2006.01.015 · DOI
- Schifano, 2016, The consequences of drug misuse on post-marketing surveillance, Exp. Rev. Clin. Pharmacol., 9, 867, 10.1080/17512433.2016.1178571 · DOI · Paper page
Cited by
Schifano, F., Chiappini, S., Corkery, J. M., & Guirguis, A. (2019) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyz007 · Cited by 194
“, 2018), which is at times occurring within the context of the rising levels of novel psychoactive substances misuse (Schifano et al., 2018).”
Self-citationNew/emerging psychoactive substances and associated psychopathological consequences
Schifano, F., Napoletano, F., Chiappini, S., Guirguis, A., Corkery, J. M., Bonaccorso, S., Ricciardi, A., Scherbaum, N., & Vento, A. (2021) · Psychological Medicine · doi:10.1017/s0033291719001727 · Cited by 119
Self-citationPregabalin: A range of misuse‐related unanswered questions
Schifano, F., & Chiappini, S. (2019) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.13115 · Cited by 36
Self-citationChiappini, S., Schifano, F., Corkery, J. M., & Guirguis, A. (2020) · Brain Sciences · doi:10.3390/brainsci10020105 · Cited by 33
Self-citationComing Off Prescribed Psychotropic Medications: Insights from Their Use as Recreational Drugs
Schifano, F. (2020) · Psychotherapy and Psychosomatics · doi:10.1159/000507897 · Cited by 18
Self-citation
Metadata
- Authors
- Schifano, F., Chiappini, S., Corkery, J., & Guirguis, A.
- Venue
- Brain Sciences
- Publisher
- MDPI AG
- Published
- 2018-04-22
- Volume
- 8
- Issue
- 4
- Pages
- 73
- ISSN
- 2076-3425 (ISSN-L)
- OpenAlex
- W2802428576
- Cited by
- 93
- References
- 31
- FWCI
- 2.89
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Abuse of Prescription Drugs in the Context of Novel Psychoactive Substances (NPS): A Systematic Review. https://app.cochat.ai/papers/10.3390/brainsci8040073
- The paper
- Schifano, F., Chiappini, S., Corkery, J., & Guirguis, A. (2018). Abuse of Prescription Drugs in the Context of Novel Psychoactive Substances (NPS): A Systematic Review. Brain Sciences. https://doi.org/10.3390/brainsci8040073
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.